ESTEVE RATED ’EXCELLENT’ FOR ITS R&D ACTIVITIES
Awarded by Profarma, the official seal of quality of the Ministry of Industry that fosters research and competitiveness in the pharmaceutical sector.
One more year -uninterruptedly so for the 27 years of history of the Profarma Plan-, ESTEVE has been awarded the highest qualification for its research, development and innovation (R&D&i) activities.
Specifically, ESTEVE comes under Group A of the Profarma Plan (2009-2012), composed of innovative pharmaceutical companies that carry out truly significant research activities and have their own production plant or R&D center.
The Profarma Plan is a joint initiative of the Industry, Energy and Tourism, Health, Social Services and Equality, Economy and Competitiveness, Ministries. It is designed to favor the sector's modernization and provide added value with activities such as R&D. These activities are rated as 'Fair', 'Good', 'Very Good' or 'Excellent' according to scientific, economic and industrial standards.
From the very beginning, back in 1929, innovation has been ESTEVE's hallmark and the key to its growth. ESTEVE presently offers a portfolio of highly innovative projects designed to provide solutions to unmet medical needs likely to have a significant impact on society. Special emphasis is placed on analgesia, where two projects in clinical phase stand out for the treatment of moderate to severe chronic pain and neuropathic pain, respectively.
ESTEVE is involved in HIVACAT, a research program devoted to developing an AIDS vaccine. HIVACAT is a public private consortium that joins the efforts of ESTEVE, the Hospital Clínic of Barcelona and the Hospital Germans Trias i Pujol of Badalona, as well as the additional support from the 'La Caixa' foundation and the Catalan Government (Generalitat de Catalunya). Also worth mentioning is the project now conducted jointly with the Center for Animal Biotechnology and Gene Therapy (CBATEG) of the Autonomous University of Barcelona for the development of gene therapy to treat the Sanfilippo syndrome Type A, a rare but devastating childhood disease. All these projects have been supported by the Spanish Ministry of Economy and Competitiveness.
At the European level, ESTEVE takes part in four projects IMI (Innovative Medicines Initiative, driven by the European Federation of Pharmaceutical Industries and Associations, EFPIA, and the European Union), such as EUROPAIN, focusing on chronic pain research, and where ESTEVE is the only Spanish pharmaceutical company involved in the program.
For more information www.esteve.com/research-development
You can follow ESTEVE on Twitter at: twitter.com/esteve_news.
THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’
Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...read more
PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES
Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...read more
ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER
ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...read more